Kiniksa Expects KPL-387 Phase 3 Data in Second Half of 2027
Kiniksa Pharmaceuticals expects pivotal Phase 3 data for KPL-387 in the second half of 2027.
Related stories
Granite Construction Reports Quarterly Results
Granite Construction reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 04:31 PM UTC
Perrigo Announces Quarterly Dividend of $0.29 Per Share
Perrigo announced a quarterly dividend of $0.29 per share.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
Euro Stoxx Index Rises 0.73%
Euro zone blue chips are up 0.64%.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
FTSE 100 rises 0.29%; DAX gains 1.36%
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
France's CAC 40 rises 1.12%; Spain's IBEX falls 0.27%
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC
US session market picture: S&P 500 -0.4%, Nasdaq 100 -1.37%; EUR/USD +0.06%, WTI -1.52%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.4 percent, Nasdaq futures is down 1.37 percent, Dow futures is down 0.44 percent and Russell futures is up 1.
M impact | EQUITY | Oct 29, 2026, 04:30 PM UTC